# Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

> **NCT03106155** · PHASE2 · TERMINATED · sponsor: **Samsung Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** vistusertib (AZD2014)

## Key facts

- **NCT ID:** NCT03106155
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-02
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-06-29
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Decision of IP support organization
- **Last updated:** 2018-09-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03106155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03106155, "Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03106155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*